Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis
J. Clin. Invest. Alexander Visekruna, et al. 116:3195 doi:10.1172/JCI28804 [Go to this article.]

Figure 7
Proteasome inhibitor secreted by probiotic bacteria inhibits the chymotrypsin-like activity of 20S proteasomes isolated from CD patients and prevents nascent colitis in IL-10 KO mice. (A) The chymotrypsin-like activity of 20S proteasomes (2 μg) purified from CD patients (n = 6) was measured in the presence (50 μl) or absence of conditioned media from probiotic bacteria (VSL#3) and E. coli strain Nissle 1917. As control, the synthetic proteasome inhibitor MG132 was used at a concentration of 10 μM. (B) IL-10 KO mice were treated before the onset of colitis either with PBS- (control) or VSL#3-conditioned medium. Treatment started at the age of 10 weeks and was performed for 3 weeks by giving either 500 μl PBS or VSL#3 intragastrically every other day. Weight was monitored for both groups (n = 8).